Related Experiment Video

Updated: Apr 6, 2026

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.8K

ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy

Marie Morfouace1, Satish Cheepala2, Sadhana Jackson1

  • 1Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Cancer Research
|July 23, 2015
PubMed

Insights

Group 3 medulloblastoma overexpresses the ABCG2 transporter, contributing to drug resistance. Inhibiting ABCG2 enhances chemotherapy effectiveness, offering a new treatment strategy for this aggressive brain cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • ATP-binding cassette (ABC) transporters can mediate chemotherapeutic drug resistance.
  • Expression and function of ABC transporters in Group 3 (G3) medulloblastoma remain largely uncharacterized.
  • G3 medulloblastoma is a therapeutically challenging pediatric brain tumor.

Purpose of the Study:

  • To investigate the expression and function of plasma membrane ABC transporters in G3 medulloblastoma.
  • To determine if ABCG2 inhibition can sensitize G3 medulloblastoma to chemotherapy.

Main Methods:

  • Quantitative analysis of ABC transporter expression in human and mouse G3 medulloblastoma.
  • In vitro drug screening using mouse G3 medulloblastoma tumorspheres.
  • In vivo studies evaluating the efficacy of combined Abcg2 inhibition and topotecan treatment.

Main Results:

  • ABCG2 was highly upregulated in G3 medulloblastoma.
  • Abcg2 protein localized to the plasma membrane and was functional in exporting substrates.
  • Abcg2 inhibition significantly potentiated topotecan's antiproliferative effect (over 9-fold) in vitro.
  • Combined Abcg2 inhibition and topotecan treatment improved survival in a preclinical mouse model.

Conclusions:

  • ABCG2 is a key mediator of drug resistance in G3 medulloblastoma.
  • Targeting ABCG2 represents a promising strategy to enhance topotecan efficacy.
  • This study provides a preclinical proof of concept for combining Abcg2 blockade with chemotherapy in G3 medulloblastoma treatment.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.2K

Related Concept Videos

ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
7.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
135